|Day Low/High||232.02 / 236.24|
|52 Wk Low/High||94.75 / 242.38|
Use buy-write orders as a conservative way to invest in GILD in these uneasy times.
Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.
The market has given up some of its early gains, but the major indices are all still in the black. Homebuilders have given up their 1% rally early today and now are flat. The Atlanta Fed's GDPNow has the economy growing 1.7% now from the last readin...
Less than a hour to go before the market open as we await the last trading day of the first quarter. Pre-market futures are still pointing to a up opening. Gilead Sciences is up some 2% this morning after developmental partner Galapagos announced so...
Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.
There are a variety of players that should be active in the M&A space next year.
Buyers expect a dovish Fed and are still trying to put money to work.
The biotech juggernaut still has a lot going for it, especially at these levels.
With low multiples and solid yields, these names look good for the long term.
Celgene, AbbVie and Gilead are set to report earnings. Here's what to look for.
Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%.